| Autor: |
Elghawy O; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Yang AG; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Sussman JH; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Thomas CJ; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Carter JS; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Svoboda J; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Kim E; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Rook AH; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Chung J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Villasenor-Park J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Plastaras JP; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., LaRiviere M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Hubbeling H; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Chelius M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Nasta SD; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Chong EA; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Schuster SJ; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Barta SK; Lymphoma Program, Abramson Cancer Center, Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: stefan.barta@pennmedicine.upenn.edu. |
| Abstrakt: |
Competing Interests: Conflicts of interest Dr Landsburg received research funding from Curis, Takeda, and Triphase; and served on the board of directors or advisory committees or data and safety monitoring board for Incyte, ADCT, Karyopharm, and Morphosis. Dr Svoboda served as a consultant for Genmab, Adaptive, AstraZeneca, BMS, Imbrium, ADCT, Atara, Pharmacyclics, and Seattle Genetics; and received research funding from AstraZeneca, BMS, Incyte, Merck, Seattle Genetics, Pharmacyclics, and TG therapeutics. Dr Nasta received research funding from Pharmacyclics, Roche, Rafael, and FortySeven/Gilead. Dr Chong served as a consultant for Genmab/AbbVie, AstraZeneca, and Beigene; and received research funding from AbbVie, AstraZeneca, CARGO, Genentech, Genmab, and Nurix. Dr Schuster served as a consultant to AstraZeneca, BeiGene, Celgene, Genentech, Genmab, Fate Therapeutics, Roche, Incyte, Juno Therapeutics, Legend Biotech, Loxo Oncology, MorphoSys, Mustang Biotech, Nordic Nanovector, Novartis, and Regeneron; received research funding from AbbVie, Adaptive Biotechnologies, Celgene, DTRM, Genentech, Roche, Juno Therapeutics, Merck, Novartis, Incyte, Pharmacyclics, and TG Therapeutics; received honoraria from Celgene and Novartis; Stefan Bartaserved as a consultant to Acrotech, Kyowa Kirin, Daiichi Sankyo, and Seagen. Drs Elghawy, Yang, Sussman, Thomas, Carter, Kim, Rook, Chung, Villasenor-Park, Plastaras, LaRiviere, Hubbeling, and Chelius have no conflicts of interest to declare. |
Full Text from ScienceDirect